US FTC challenges more than 100 patents as improperly listed in FDA’s Orange Book
MLex Summary: The US Federal Trade Commission announced challenges to more than 100 patents held by manufacturers of brand-name asthma inhalers, epinephrine autoinjectors, and other drug products as improperly or inaccurately...To view the full article, register now.
Already a subscriber? Click here to view full article